# Climb Bio, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Climb Bio, Inc.). ## Overview Climb Bio, Inc. is a clinical-stage biotechnology company developing antibody therapeutics for immune-mediated diseases. Its pipeline is built through acquisitions and in-licensing, with lead programs budoprutug and CLYM116 aimed at B-cell and APRIL biology across multiple autoimmune indications. ## Products & services • Budoprutug anti-CD19 monoclonal antibody • CLYM116 anti-APRIL monoclonal antibody • Clinical development for pMN, ITP and SLE • In-licensed and acquired therapeutic pipeline assets - **Lead antibody candidate: budoprutug** (50%) — Clinical-stage anti-CD19 monoclonal antibody being developed for immune-mediated diseases. - **Second antibody candidate: CLYM116** (30%) — Anti-APRIL monoclonal antibody licensed for development and commercialization outside Greater China. - **Clinical development programs** (20%) — Preclinical and clinical work across pMN, ITP, SLE and other immune-mediated indications. - Budoprutug, a clinical-stage anti-CD19 monoclonal antibody - CLYM116, an anti-APRIL monoclonal antibody - Development programs in primary membranous nephropathy, ITP and SLE - Pipeline assets acquired or in-licensed for immune-mediated diseases ## Customers Climb Bio does not yet sell approved products, so its near-term 'customers' are clinical investigators, trial sites, regulators and future payors rather than end patients. If approved, the commercial buyers would be physicians, hospitals, specialty pharmacies and third-party payors treating patients with immune-mediated diseases. The target end markets are patients with pMN, ITP, SLE and other B-cell driven autoimmune conditions. - **Clinical investigators and trial sites** (primary) — They run the company’s studies and generate the data needed to advance budoprutug and CLYM116. - **Regulators** (primary) — FDA and other agencies evaluate the clinical package and determine whether the candidates can be approved. - **Physicians treating autoimmune disease** (primary) — Future prescribers for pMN, ITP and SLE if the products reach market; they will choose based on efficacy and safety. - **Third-party payors** (secondary) — Insurers and government payors will determine coverage and reimbursement, which will shape uptake. - Clinical trial sites and investigators running budoprutug studies - Regulators reviewing safety and efficacy data for approval - Future physicians treating pMN, ITP and SLE patients - Hospitals and specialty pharmacies if products are commercialized - Third-party payors that will influence access and reimbursement ## Geography Climb Bio is headquartered in the United States and conducts its development activities through a U.S.-based clinical-stage organization. The company has worldwide rights to budoprutug except oncology, and rights to CLYM116 worldwide outside Greater China, so future commercialization could span multiple regions if approvals are obtained. At present, it has no product sales and no disclosed country-level revenue. - Headquartered in Wellesley Hills, Massachusetts, United States - Clinical development and corporate functions are U.S.-based - Budoprutug rights are worldwide except oncology - CLYM116 rights exclude mainland China, Hong Kong, Macau and Taiwan - No approved products and no disclosed product revenue yet ## Strategy The company’s strategy is to build a focused pipeline in immune-mediated diseases using assets with clear biological rationale and defined development paths. It is prioritizing budoprutug in pMN, ITP and SLE while expanding the platform with CLYM116 to broaden its B-cell targeted franchise. Because it has no manufacturing footprint and no commercial revenue, execution depends on clinical progress, licensing economics and access to external capital. - **Advance budoprutug in pMN, ITP and SLE** (short-term) — These indications have a strong mechanistic rationale and could validate the lead asset across multiple autoimmune markets. - **Develop CLYM116 as a second B-cell targeted program** (medium-term) — Adds pipeline depth and diversifies the company beyond a single lead asset. - **Secure external funding and partnerships** (short-term) — The company has no product revenue and will need capital to fund trials and commercialization. - Advance budoprutug through clinical development in selected autoimmune indications - Use in-licensed and acquired assets to reduce early discovery risk - Expand the B-cell targeted pipeline with CLYM116 - Rely on CDMOs rather than internal manufacturing capacity - Preserve capital through focused development and external financing ## Risks Climb Bio is exposed to the classic risks of an early-stage biotech: clinical failure, regulatory delay, and the need for repeated capital raises before any product revenue exists. Its commercial opportunity also depends on payer coverage, physician adoption and competition from better or faster-moving autoimmune therapies. Because it relies on third-party CDMOs and has no commercial infrastructure, supply chain, manufacturing and launch execution risks are also material. - **Clinical development failure or delay** [critical] — Budoprutug and CLYM116 are still in development and may not show sufficient safety or efficacy. - **Need for additional capital** [high] — The company has no product revenue and expects continued operating losses, so funding needs are ongoing. - **Competitive pressure in autoimmune disease** [high] — Large pharma and biotech peers may launch superior or earlier therapies, limiting market share and pricing. - **Manufacturing and supply dependence on CDMOs** [medium] — The company does not own manufacturing facilities and relies on third parties for clinical and future commercial supply. - No approved products, so value depends on clinical and regulatory success - Ongoing losses and cash needs may force dilutive financing - Competition could produce safer, more effective or cheaper therapies - Third-party CDMO dependence creates supply and quality execution risk - Reimbursement and physician adoption will determine future uptake ## Accounting The most important accounting issue is research and development expense accruals, because the company must estimate CRO and CDMO costs before invoices arrive. As a clinical-stage biotech with no product revenue, reported losses are driven largely by trial spending, licensing costs and stock-based compensation rather than operating sales. Investors should also watch capital-raise accounting and any future fair value or impairment judgments tied to acquired or licensed intangible assets. - **Research and development accruals** — Affects operating loss, accrued liabilities and period-to-period comparability - **Stock-based compensation** — Can materially increase non-cash operating expense - **Impairment and valuation of acquired/licensed assets** — Could affect intangible assets and future earnings - R&D accrual estimates affect reported operating losses and cash burn - Stock-based compensation can materially affect G&A and R&D expense - No product revenue yet, so future revenue recognition will be event-driven - Acquired or licensed assets may require impairment or fair value judgments - Capital raises and preferred stock history affect equity accounting --- *Last updated: 2026-04-28T19:58:19.619725+00:00*